{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["21(10)"],"submitter":["Stasi C"],"pubmed_abstract":["<h4>Aim</h4>To evaluate the association between liver stiffness (LS) prior to the initiation of dual/triple therapy and viral response.<h4>Methods</h4>LS was measured in all patients before treatment was administered. The therapeutic approach was based on hepatic, virological, and immunological evaluations and considered the fact that patients with severe fibrosis (F3) or compensated cirrhosis (F4) in Child-Pugh class A are the primary candidates for triple therapy. In total, 65 hepatitis C virus (HCV) patients were treated with Peg-interferon/ribavirin (Peg-IFN/RBV); 24 patients were classified as genotypes 1/4 (36.92%), and 41 patients were classified as genotypes 2/3 (63.08%) (dual therapy). In addition, 20 HCV treatment-experienced genotype 1 patients were treated with PegIFN-RBV and b"],"journal":["World journal of gastroenterology"],"pagination":["3013-9"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4356922"],"repository":["biostudies-literature"],"pubmed_title":["Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study."],"pmcid":["PMC4356922"],"pubmed_authors":["Monti M","Piluso A","Milani S","Marra F","Salomoni E","Boldrini B","Zignego AL","Laffi G","Corti G","Montalto P","Arena U","Stasi C"],"additional_accession":[]},"is_claimable":false,"name":"Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study.","description":"<h4>Aim</h4>To evaluate the association between liver stiffness (LS) prior to the initiation of dual/triple therapy and viral response.<h4>Methods</h4>LS was measured in all patients before treatment was administered. The therapeutic approach was based on hepatic, virological, and immunological evaluations and considered the fact that patients with severe fibrosis (F3) or compensated cirrhosis (F4) in Child-Pugh class A are the primary candidates for triple therapy. In total, 65 hepatitis C virus (HCV) patients were treated with Peg-interferon/ribavirin (Peg-IFN/RBV); 24 patients were classified as genotypes 1/4 (36.92%), and 41 patients were classified as genotypes 2/3 (63.08%) (dual therapy). In addition, 20 HCV treatment-experienced genotype 1 patients were treated with PegIFN-RBV and b","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Mar","modification":"2025-04-04T19:20:40.033Z","creation":"2019-03-27T01:48:02Z"},"accession":"S-EPMC4356922","cross_references":{"pubmed":["25780300"],"doi":["10.3748/wjg.v21.i10.3013"]}}